PubMed Health⌕ Search

Biomedical subjects

J H Ransom

Publications and source records attributed to J H Ransom.

At least 37 records · Page 2Linked to original sources

Leukoregulin inhibits the growth of human glioblastoma in vitro.

Growth of cultured human glioblastoma cells was profoundly inhibited by concentrated lymphokines prepared from mitogen-activated blood mononuclear cells of normal donors. Cloning efficiency of glioma cells and their absolute number were decreased as well. Partially purified leukoregulin, free of lymphotoxin, tumor necrosis factor and gamma-interferon, similarly suppressed DNA synthesis and clonogenicity. The decrease in absolute numbers of tumor target cells indicated that leukoregulin was directly cytolytic as well as cytostatic for human glioblastoma cells. Our data indicate that leukoregulin is at least one of the factors produced by activated lymphocytes which inhibits the proliferation of human glioblastoma in vitro.

Cell Cycle↗

Leukoregulin, a direct-acting anticancer immunological hormone that is distinct from lymphotoxin and interferon.

Human lymphokine preparations can directly lyse or suppress proliferation of human tumor cells or can enhance the susceptibility of human tumor cells to lysis mediated by natural killer lymphocytes. In the past, these antitumor activities were attributed to lymphotoxin. This study demonstrates, however, that these human lymphokine antitumor cell activities are biochemically separable from lymphotoxin and are properties of a lymphokine which was named leukoregulin because it is produced by lymphocytes and it regulates target cell physiology and growth. Leukoregulin obtained by high-performance liquid chromatography and isoelectric focusing was free of detectable lymphotoxin, interferon, interleukins 1 and 2, and macrophage-activating factor activities. Leukoregulin has an apparent molecular weight of 135,000 as measured by linear gradient polyacrylamide gel electrophoresis and gel filtration chromatography and has isoelectric pHs of approximately 5.3 and 7.5. The molecular weight of leukoregulin, determined in the dissociating conditions of sodium dodecyl sulfate polyacrylamide gel electrophoresis, was 32,000. Flow cytometric analysis showed that tumor cell lysis, growth inhibition, and enhancement of susceptibility to natural killer cell-mediated cytotoxicity by leukoregulin were accompanied by rapid alterations in tumor cell membrane permeability. Lymphotoxin from human peripheral blood leukocytes and highly purified lymphotoxin from RPMI 1788 human lymphoblastoid cells lysed murine alpha-L929 tumor cells but did not possess any of the direct acting antihuman tumor cell cytostatic, cytolytic, or natural killer cell enhancing activities that leukoregulin exhibited against a broad spectrum of human tumor cell lines. The dual modes of the anticancer actions of leukoregulin, direct cytotoxicity and indirect enhancement of natural killer cell cytotoxicity, make leukoregulin a unique-acting lymphokine and suggest several ways in which leukoregulin may be used as a therapeutic agent against cancer.

Cell Line↗

Lymphotoxin amplification of tumor growth inhibition is specific for natural killer cells but not for macrophages.

Lymphotoxin augments the susceptibility of tumorigenic guinea-pig cells to natural killer (NK) cell cytolysis in vitro but does not directly stimulate either NK cell or macrophage cytolytic action. The question whether lymphotoxin enhances the susceptibility of tumorigenic guinea-pig cells to cytolysis or other means of growth inhibition in vivo by syngeneic NK cells or macrophages was, therefore, examined using a modified tumor cell neutralization (Winn) assay. Mineral oil-, thioglycollate- or casein-induced peritoneal leukocytes, but not the macrophages isolated from the elicited leukocytes obtained from nonimmunized strain 2/N guinea-pigs, effected enhanced cytolysis of lymphotoxin-treated guinea-pig benzo (a)pyrene-induced 104CI tumor cells in vitro. Neither guinea-pig splenic NK cells nor oil-induced peritoneal macrophages alone inhibited the growth of 104CI cells as tumors in vivo when admixed with 104CI cells and injected into guinea-pigs. However, when the 104CI cells were treated with lymphotoxin before addition of effector cells, NK cells but not macrophages significantly reduced tumor growth in vivo. Therefore, the ability of lymphotoxin to increase the sensitivity of tumor cells to destruction mediated by natural leukocytes is specific for NK cells as compared to macrophages. This form of lymphokine amplification of natural leukocyte cytotoxicity may be one mechanism by which natural and acquired immunity serves or fails to prevent cancer and should be an important consideration in therapeutic approaches to eradicate or control tumor growth.

Animals↗

Endothelial cell growth supplement: a cell cloning factor that promotes the growth of monoclonal antibody producing hybridoma cells.

The efficiency of endothelial cell growth supplement (ECGS), a commercially marketed extract of bovine neural tissue, human endothelial cell supernatant (HECS) derived from freshly isolated endothelial cells, and feeder layers of murine peritoneal cells (PEC), were compared for their ability to support cell fusion, clonal growth, and monoclonal antibody production of murine hybridoma cells. ECGS at 25-100 micrograms/ml was similar to a 1:5 dilution of HECS in supporting the growth of hybridoma colonies; both ECGS and HECS were superior to PEC feeder cells. Furthermore, hybridomas cloned in ECGS produced anti-lymphotoxin antibodies. The commercial availability and stability of ECGS together with its ability anti-lymphotoxin antibodies. The commercial availability and stability of ECGS a superior growth supplement for the fusion and growth of hybridoma cells in monoclonal antibody production.

Animals↗

Control of the carcinogenic potential of 99mTechnetium by the immunologic hormone lymphotoxin.

Immunologic prevention of the carcinogenicity of the diagnostic gamma-emitting radionuclide 99mTechnetium (99mTc) by lymphotoxin was evaluated using an in vivo-in vitro assay of carcinogenesis. Pregnant Syrian golden hamsters received 125-2,300 microCi 99mTc/kg body weight by injection, and 7 days later colonies of morphologically transformed cells were quantitated in vitro. The transformation frequency increased directly with the radionuclide concentration, and cells derived from transformed colonies produced tumors in athymic nude mice. The total absorbed 99mTc dose was 0.20 rad following injection of 250 microCi 99mTc/kg hamster body weight; this compares with an exposure of 0.13 rad following injection of 143 microCi 99mTc/kg body weight in humans. Intravenous injection of purified hamster lymphotoxin immediately after 99mTc caused a dose-dependent reduction in the transformation frequency. Transformation was essentially completely prevented (97%) by injection of 8,000 U of lymphotoxin. Thus, the immune system, through the action of lymphotoxin, has the potential to prevent carcinogenesis induced by gamma-radiation from 99mTc. This emphasizes the importance of considering the recipient's immune and other homeostatic mechanisms as part of a complete diagnostic or therapeutic gamma-radiation regimen.

Animals↗

Identification of beta-lymphotoxin as the predominant molecular class of in vitro and in vivo Syrian hamster lymphotoxin.

The molecular class of Golden Syrian hamster lymphotoxin produced in vitro and in vivo was determined by size-exclusion high-performance liquid chromatography using silica-based protein separation columns eluted with a 0.1 M sodium phosphate, pH 7.4 buffer containing 0.1% Mr 4000 polyethylene glycol. Lymphotoxin cytolytic activity was quantitated in the column effluent by measuring the ability of the fractions to lyse alpha-L929 cells as indicated by [3H]TdR release. Lymphotoxin activity induced by an 8- or 24-hr or 5-day phytohemagglutinin stimulation of peritoneal leukocytes, by 24-hr phytohemagglutinin-coated alpha-L929-cell stimulation of peritoneal leukocytes, or by 24-hr phytohemagglutinin stimulation of spleen cells occurred in the Mr range of 20,000-56,000, with major components in the 35,000-50,000 beta-lymphotoxin region. No activity was present in the complex (greater than 200,000) region and only minimal activity was detectable in the alpha (70,000-160,000) and gamma (12,000-20,000) regions. In vivo-induced lymphotoxin, obtained by peritoneal lavage 48 hr after intraperitoneal administration of phytohemagglutinin, was entirely beta-lymphotoxin and was not detectable in the plasma. Lymphotoxin produced in vitro and injected simultaneously with the gamma-emitting radionuclide 99mtechnetium, inhibited in vivo development of radiation-induced transplacental carcinogenesis. Thus, Syrian hamster lymphotoxin with antitumor activity consists of glycoproteins with isoelectric points of 4.8-5.2, Mr of 20,000-56,000, and major in vitro and in vivo forms in the beta-lymphotoxin range.

Animals↗

Molecular and biological characterization of anticarcinogenic and tumor cell growth-inhibitory activities of Syrian hamster lymphotoxin.

Syrian hamster lymphotoxin has three identified anticancer activities: (a) cytolytic activity measured as the release of 3H from [3H]thymidine-labeled murine alpha L-929 cells; (b) cytostatic activity assessed by the inhibition of cell colony formation of tumorigenic Syrian hamster cells; and (c) anticarcinogenic activity measured by inhibition of chemical carcinogen or radiation-induced morphological transformation of Syrian hamster fetal cells in vitro and in vivo. Lymphotoxin cytolytic, cytostatic, and anticarcinogenic activities have similar molecular weights of approximately 45,000 by ACA-44 Ultrogel chromatography. A three-step purification of (a) diafiltration and concentration, (b) column isoelectric focusing in a pH 4 to 6 gradient, and (c) ACA-44 Ultrogel column chromatography yields 25% recovery of lymphotoxin cytolytic and anticarcinogenic activities. The three-step purified lymphotoxin is free of detectable interferon, macrophage migration inhibitory factor, and mitogenic factors inducing hamster T-lymphocyte proliferation and is anticarcinogenic in vivo. The purified lymphotoxin had a specific anticarcinogenic activity of 58,500 units/mg of protein and a molar specific activity of 2,900 units/nmol. Although homogeneous in molecular size, the purified lymphotoxin is comprised of several molecular species. Cytolytic activity is associated with molecules having a single major isoelectric point of 5.0, whereas the cytostatic and anticarcinogenic activities comigrate with molecules with major isoelectric points of 5.0 and 4.6. This is the first evidence that the anticancer actions of lymphotoxin are properties of similarly sized but several different electrically charged molecules and that the several lymphotoxin species have differing anticancer activities.

Animals↗

Lymphotoxin enhances the susceptibility of neoplastic and preneoplastic cells to natural killer cell mediated destruction.

Treatment of neoplastic guinea-pig cells for 1-14 days with 300 units of guinea-pig lymphotoxin/ml medium enhanced 2- to 5-fold their susceptibility to natural killer (NK) cell-mediated cytotoxicity as measured by 4 h 51Cr and 72 h [3H]-thymidine-release assays. The NK susceptibility of human neoplastic and guinea-pig non-neoplastic cells refractory to guinea-pig lymphotoxin growth-inhibitory activity was unchanged after lymphotoxin treatment. Lymphotoxin preparations were free of detectable interferon and the enhancing activity copurified with lymphotoxin during diafiltration and isoelectric focusing. Treatment of NK cells with lymphotoxin preparations also augmented NK-mediated lysis but that activity did not copurify with lymphotoxin. As with neoplastic cells, lymphotoxin-sensitive preneoplastic cells previously treated with ultraviolet light, a chemical carcinogen, or carcinogen and the tumor-promoting agent tetradecanoylphorbol-acetate also exhibited lymphotoxin enhancement to NK-cell destruction. Thus, the immunologic hormone lymphotoxin enhances the susceptibility of lymphotoxin-sensitive cells to NK-cell destruction, indicating that these two natural immune mediators, lymphotoxin and NK cells, have the potential in concert to regulate carcinogenesis and neoplastic growth.

Animals↗

Kinetics of the immune response of tumor-bearing hamsters to two simian virus 40 coded non-structural polypeptides present in simian virus 40 tumor cells.

The kinetics of the immune response of hamsters transplanted with virus-free SV40 tumor cells (TSV5) to two SV40-coded non-structural proteins of 94,000 daltons (T antigen) and 17,000 daltons (t antigen) was studied in order to determine if the variation in the immune reactivity of serum from tumor-bearing animals towards these proteins can be explained on the basis of differential immune response during various stages of tumor growth. The results demonstrate that individual animals vary in their capacity to respond immunologically to T and t antigens in SV40-transformed cells and that, further, the immune response to T and t antigens is influenced by the stage of tumor development.

Animals↗

Lymphotoxin prevention of diethylnitrosamine carcinogenesis in vivo.

Development of intervention measures to control cancer would be facilitated by being able to monitor in vivo carcinogenesis by in vitro quantitation of early indices of neoplastic transformation to assess the in vivo effectiveness of preventive-therapeutic measures. Pregnant Syrian golden hamsters were used in an in vivo-in vitro transplacental model of carcinogenesis to determine the extent that in vivo administration of immunologic hormone preparations along with chemical carcinogen would prevent morphologic transformation assessed in vitro. Pregnant hamsters at 10-11 days of gestation were given injections ip of 3 mg diethylnitrosamine (DENA)/100 g body weight and were killed 2 days later when fetal cells were seeded for colony formation. The frequency of morphologically transformed colonies was assessed after 7 days of growth. Cloning efficiency and mean transformation frequency after DENA exposure were 3.6% and 1 X 10(-4) per cell seeded, respectively. The ip injection of an immunologic hormone preparation reduced the transformation frequency by 46%. The hormone preparation, containing 10,000 U of lymphotoxin but no detectable interferon, was the ultrafiltered lymphokines (greater than 10,000 mol wt) from phytohemagglutinin-stimulated hamster peritoneal leukocytes. The effect of lymphotoxin on cocarcinogenic exposure of fetal cells to DENA in vivo followed by X-irradiation in vitro was also determined. Cells exposed to 250 rad in vitro had a cloning efficiency of 0.5% and a transformation frequency of 0.4 X 10(-4) per cell seeded. After DENA injection and X-irradiation, the transformation frequency increased to 1 X 10(-4) and was inhibited 64% by lymphotoxin in vivo. Thus immunologic hormones (e.g., lymphotoxin) can prevent carcinogenesis in vivo. Furthermore, in vitro quantitation of transformation is a rapid means for evaluating therapeutic and autochthonous effector mechanisms for their ability to prevent or otherwise modulate carcinogenesis in vivo.

Animals↗

Solubilization and partial characterization of a tumor-rejection antigen from an ultraviolet light-induced murine tumor.

Tumor rejection antigen (TRA) of an ultraviolet-light-induced murine skin tumor was solubilized, fractionated and partially characterized. Subcellular fractions were prepared by differential centrifugation of tumor cells that had been ruptured via nitrogen cavitation. Only the 110,000-g membrane fraction induced significant tumor protection, as determined by in vivo immunization and challenge assays. Extraction of the membrane fraction with 3 M KCI resulted in solubilization of material that could induce in vivo tumor-rejection immunity. Both the membrane fraction and soluble extract had a limited effective dose range. The KCI extract was separated on a Sepharose, CL-6B column in the presence of 6 M guanidine-HCI. Only one of five fraction pools (molecular weight range of 76,000-127,000 daltons) was immunogenic. It contained at least eight protein bands by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), but no lipid components. This immunogenic Sepharose fraction was chromatographed on a Sephadex G-150 column. Each of the four Sephadex fraction pools was immunogenic. One protein component was common to each of those fractions. It migrated as a single 76,000-dalton band on SDS-PAGE and contained [14C]-leucine and [3H]-glucosamine that had been incorporated during cell growth. These results suggest that the TRA of this tumor is a 76,000-dalton glycoprotein.

Animals↗

Allergic reactions to enzymes used in plant cloning experiments.

We report a case of rhinitis and asthma resulting from exposure to enzymes used in an experimental plant pathology laboratory. Immediate skin-test responses were elicited to both "Cellulase" and "Macerozyme" products, and a large late onset skin reaction occurred at the Cellulase site beginning in 6 hr. Special radioallergosorbent test (RAST) substrates were prepared that showed a strong positive response to Cellulase. By the RAST method other laboratory workers were screened and another symptomatic individual was found who also showed evidence of type I hypersensitivity to both enzymes. Skin biopsy and immunodiffusion data are presented. We conclude that enzymes used to digest cell wall structures of plants are capable of eliciting both immediate and late onset skin-test reactions and positive RAST responses in susceptible persons. These reactions are thought to be mediated by IgE antibodies and can be associated with symptoms of rhinitis and asthma.

Adult↗

Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.

Fifteen patients undergoing surgery for Stage IIb malignant melanoma were randomly allocated either to a group who received a vaccine of BCG mixed with irradiated autologous melanoma cells, or a control group who received no further treatment. All patients were monitored sequentially for immunological competence and tumour-directed immunity, using a wide range of techniques, and the results were compared retrospectively with their clinical course. Three months after surgery, there was a trend towards inhibition of PHA-induced lymphocyte transformation by autologous serum in patients who developed recurrent tumour within 12 months after treatment. Serum from patients who remained tumour-free for 12 months did not inhibit stimulation of autologous lymphocytes by PHA. Apart from this test, no other immunological parameters correlated either with clinical course or with the type of treatment received.

Antibody Formation↗

Vox dox.

Explore the source record for details and available documents.

Asthma↗